Case Control Study
Copyright ©The Author(s) 2021.
World J Diabetes. Feb 15, 2021; 12(2): 138-148
Published online Feb 15, 2021. doi: 10.4239/wjd.v12.i2.138
Table 1 Baseline characteristics, disease information and laboratory data of the healthy controls, without diabetic retinopathy, non-proliferative diabetic retinopathy and proliferative diabetic retinopathy groups
Healthy controls (n = 118)DM
P value

NDR (n = 57)
NPDR (n = 64)
PDR (n = 61)
Baseline characteristics
Gender (male, %)56 (48.70)27 (47.37)26 (40.63)29 (47.54)0.947
Age (yr)59.84 ± 9.6058.21 ± 7.7560.89 ± 9.9365.72 ± 8.36< 0.001
BMI (kg/m2)26.11 ± 3.18 27.39 ± 3.71 26.86 ± 2.7625.93 ± 3.890.047
SBP (mmHg)123.53 ± 14.47 126.82 ± 17.62 131.66 ± 10.63 136.34 ± 11.87< 0.001
DBP (mmHg)73.97 ± 12.08 73.54 ± 12.69 81.14 ± 15.42 77.52 ± 13.090.0019
MAP (mmHg)90.49 ± 9.41 91.30 ± 10.86 97.98 ± 10.78 97.13 ± 10.04< 0.001
Disease information
Diabetes duration (yr)-5.72 ± 2.64 10.92 ± 6.0112.52 ± 4.96< 0.001
Fasting blood glucose (mg/dL)84.73 ± 23.85 133.81 ± 24.98143.28 ± 36.25167.86 ± 40.42< 0.001
HbA1C (%)5.87 ± 1.327.85 ± 1.698.61 ± 2.119.27 ± 1.80< 0.001
Use of oral hypoglycemic agents-38 (66.67)50 (78.13)44 (72.13)0.369
Use of insulin-15 (26.31)24 (37.50)21 (34.43)0.408
Hypertension (n, %)52 (44.07)25 (43.86)38 (59.38)41 (67.21)0.009
Smoking (n, %)37 (31.36)14 (24.56)18 (28.13)19 (31.15)0.801
Drinking (n, %)41 (34.75)20 (30.09)19 (29.69)24 (39.34)0.730
Laboratory data
Triglycerides (mmol/L)4.70 ± 1.50 4.79 ± 1.28 4.55 ± 1.28 4.88 ± 1.200.567
Total cholesterol (mmol/L)4.57 ± 1.54 5.01 ± 1.64 4.25 ± 1.77 4.77 ± 1.790.077
LDL cholesterol (mmol/L)3.12 ± 1.122.96 ± 1.20 2.98 ± 1.09 2.87 ± 0.940.504
HDL cholesterol (mmol/L)1.18 ± 0.271.14 ± 0.261.19 ± 0.291.16 ± 0.280.740
Total bilirubin (mmol/L)12.79 ± 3.3413.44 ± 3.8911.55 ± 4.0411.21 ± 3.890.002
AST (U/L)21.76 ± 9.0822.62 ± 9.1522.38 ± 8.7822.40 ± 9.600.930
ALT (U/L)21.16 ± 8.6622.78 ± 9.3523.16 ± 8.9222.61 ± 8.330.4251